Fig. 5
Targeted and effective anti-tumor activity of anti-LGALS3BP ADC 1959-sss/DM4 in murine syngeneic neuroblastoma model. (A) Tumor growth expressed as tumor volume (mm3) from first treatment of NXS2 CTRL or hLGALS3BP allografts in syngeneic A/J mice treated or not with ADC 1959-sss/DM4 (10 mg/kg; twice weekly; three total i.v. injections). Arrows indicate treatments administration. 4 or 5 mice per group were considered. (B) Kaplan-Meier curve showing probability of survival in percentage of mice bearing NXS2 CTRL or hLGALS3BP allografts treated or not with ADC 1959-sss/DM4 from first treatment. Log-rank (Mantel-Cox) test: ** p < 0.01. (C) TILs flow cytometric analysis of PBS (n = 4), 1959-sss (n = 2) and 1959-sss/DM4 (n = 4) treated tumors at 7 days after starting treatments, showing percentage of activated CD69 + within the total population of CD3+ T cells (left panel); percentage of activated CD8+ CD69+ within the total population of CD3+ T cells (middle panel). In the right panel is shown the percentage of CD69+ Granzyme B+ over cytotoxic CD8+ T cells. Differences were compared using unpaired T test, and considering significant p < 0.05, as indicated with an asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001)